Plain-English translation of NCT07138729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a newer imaging scan called 99mTc-TCR-FAPI SPECT can detect joint inflammation in rheumatoid arthritis just as well as — or better than — a standard imaging scan called 68Ga-FAPI PET/CT. Both scans use a harmless tracer (a radioactive dye) that highlights inflammation in your joints. The researchers want to know which scan is most helpful for doctors in detecting and monitoring your disease.
Rheumatoid arthritis can be hard to diagnose and monitor because inflammation doesn't always show up on standard tests or physical exams. Better imaging tools could help doctors catch the disease earlier, confirm how active it is, and track whether treatment is working.
You likely qualify if…
You likely don't qualify if…
You would visit the research center twice within a one-week period. At each visit, you'll receive one imaging scan — one will be the newer SPECT scan and one will be the standard PET/CT scan. Both scans are painless and non-invasive; you'll receive a small injection of a harmless tracer and then lie still while a camera takes pictures of your joints. Two experienced radiologists will review your scans to compare how well each one detects inflammation in your joints.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China